Oxbryta™ (voxelotor) – New orphan drug approval
November 25, 2019 - The FDA announced the approval of Global Blood Therapeutics’ Oxbryta (voxelotor), for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
Download PDF
